Display options
Cite
Jang YS, Lee ES, Kim YK. Venous thromboembolism associated with combined oral contraceptive use: a single-institution experience. Obstet Gynecol Sci. 2021;64(4):337-344doi: 10.5468/ogs.20374.
Jang, Y. S., Lee, E. S., & Kim, Y. K. (2021). Venous thromboembolism associated with combined oral contraceptive use: a single-institution experience. Obstetrics & gynecology science, 64(4), 337-344. https://doi.org/10.5468/ogs.20374
Jang, Yong-Su, et al. "Venous thromboembolism associated with combined oral contraceptive use: a single-institution experience." Obstetrics & gynecology science vol. 64,4 (2021): 337-344. doi: https://doi.org/10.5468/ogs.20374
Jang YS, Lee ES, Kim YK. Venous thromboembolism associated with combined oral contraceptive use: a single-institution experience. Obstet Gynecol Sci. 2021 Jul;64(4):337-344. doi: 10.5468/ogs.20374. Epub 2021 Apr 01. PMID: 33794564; PMCID: PMC8290149.
Copy Download .nbib Format: NLM
Share it on

Obstet Gynecol Sci. 2021 Jul;64(4):337-344. doi: 10.5468/ogs.20374. Epub 2021 Apr 01.

Venous thromboembolism associated with combined oral contraceptive use: a single-institution experience.

Obstetrics & gynecology science

Yong-Su Jang, Eun Sil Lee, Yang-Ki Kim

Affiliations

  1. Department of Obstetrics and Gynecology, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea.
  2. Department of Obstetrics and Gynecology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.
  3. Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.

PMID: 33794564 PMCID: PMC8290149 DOI: 10.5468/ogs.20374

Abstract

OBJECTIVE: Combined oral contraceptives (COCs) are used for various reasons. However, venous thromboembolism (VTE), a significant side effect, can be fatal. This study reports the first case series in Korea involving patients with COC-associated VTE registered at a university hospital.

METHODS: This study recruited 13 patients diagnosed with COC-associated VTE between June 2006 and May 2018. Risk factors, including age, body mass index, smoking habits, estrogen dosage, type of progestin, and duration of COC use, were evaluated.

RESULTS: Among patients with VTE, 9 showed pulmonary embolism (PE) concomitant with deep vein thrombosis (DVT). However, the remaining patients showed DVT (1 patient), PE (1 patient), and cerebral venous thrombosis (2 patients). The median duration between the onset of symptoms and a hospital visit was 3 days, and it sometimes took as long as 32 days. Among the 10 patients with PE, 1 high-risk group and 2 intermediate-high risk groups were treated with tissue plasminogen activators before anticoagulants. There were no cases of recurrence among patients who continued to take anticoagulants for 3 months.

CONCLUSION: These findings emphasize that healthcare professionals who prescribe or dispense COCs to women must inform them of the risk of VTE, including the risk factors, differences in risk depending on the type of progestin present in the product, and pertinent signs and symptoms. Efforts should also be made to inform patients of VTE, even through information campaigns such as brochures. Most importantly, women should remain alert for signs and symptoms of VTE when using COCs.

Keywords: Contraceptives, oral, combined; Intracranial thrombosis; Pulmonary embolism; Venous thromboembolism; Venous thrombosis

References

  1. Thromb Haemost. 2010 Sep;104(3):498-503 - PubMed
  2. Thromb Res. 2017 Mar;151 Suppl 1:S6-S10 - PubMed
  3. Contraception. 2002 Mar;65(3):187-96 - PubMed
  4. JAMA Intern Med. 2018 Nov 1;178(11):1482-1488 - PubMed
  5. Minerva Ginecol. 2012 Dec;64(6):539-49 - PubMed
  6. Cochrane Database Syst Rev. 2014 Mar 03;(3):CD010813 - PubMed
  7. Thromb Res. 2016 Sep;145:40-5 - PubMed
  8. JAMA. 2000 Jul 5;284(1):72-8 - PubMed
  9. Obstet Gynecol Sci. 2017 Mar;60(2):232-235 - PubMed
  10. Am J Obstet Gynecol. 1999 Jun;180(6 Pt 2):S357-63 - PubMed
  11. Obstet Gynecol Sci. 2013 Jul;56(4):273-6 - PubMed
  12. Thromb Res. 2014 Jul;134(1):138-43 - PubMed
  13. J Obstet Gynaecol Res. 2017 May;43(5):789-797 - PubMed
  14. Lancet. 1995 Dec 16;346(8990):1589-93 - PubMed
  15. Lancet Neurol. 2007 Feb;6(2):162-70 - PubMed
  16. J Thromb Haemost. 2007 Nov;5(11):2243-9 - PubMed
  17. J Thromb Haemost. 2007 Apr;5(4):692-9 - PubMed
  18. N Engl J Med. 2001 May 17;344(20):1527-35 - PubMed
  19. J Biol Chem. 2010 Apr 30;285(18):13444-53 - PubMed
  20. BMJ. 2009 Aug 13;339:b2890 - PubMed
  21. Hum Reprod. 2002 Dec;17(12):3235-41 - PubMed
  22. Hum Reprod Update. 2016 Sep;22(5):634-46 - PubMed
  23. Hum Reprod Update. 1999 Nov-Dec;5(6):672-80 - PubMed
  24. BMJ. 2013 Mar 07;346:f1464 - PubMed
  25. BMJ. 2011 Apr 21;342:d2139 - PubMed
  26. Thromb Res. 2016 Jan;137:11-16 - PubMed
  27. Eur J Endocrinol. 2014 Dec;171(6):R221-30 - PubMed
  28. CMAJ. 2011 Dec 13;183(18):E1319-25 - PubMed
  29. JAMA. 2004 Oct 6;292(13):1573-80 - PubMed
  30. Blood. 2006 Apr 1;107(7):2766-73 - PubMed
  31. Ann Intern Med. 2015 Jan 6;162(1):27-34 - PubMed
  32. Am J Obstet Gynecol. 1999 Jun;180(6 Pt 2):S364-8 - PubMed
  33. BMJ. 2009 Aug 13;339:b2921 - PubMed

Publication Types